- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07823088
Open Label Safety Investigation of Solutio™ Tumescent Catheter
A Prospective, Open Label Investigation of Safety of the Solutio™ Tumescent Catheter for Endothermal Ablation of Varicose Veins
The goal of this clinical investigation is to evaluate safety of the Solutio™ catheter when administering tumescent anesthesia before treatment with endothermal ablation in adults above the age of 18, who suffer from unilateral insufficiency of the great saphenous vein (GSV).
Main question(s) to answer is:
Safety evaluated through reported Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs).
Incidence of Adverse Events (AE), Adverse Device Effects (ADE), Serious Adverse Events (SAE), Serious Adverse Device Effects (SADE), and device deficiency (DD) throughout the investigation.
All investigation participants will:
- Undergo screening, including medical history, physical examination, and vein mapping with Doppler ultrasound.
- Have their Great Saphenous Vein (GSV) treated using Seldinger technique under ultrasound guidance.
- Receive tumescent anesthesia injected from inside the vein into the perivascular tissue at selected sites along the vein, using the investigational Solutio™ catheter under ultrasound guidance.
- Undergo endothermal ablation, Endovenous Laser Ablation (EVLA), or Radiofrequency Ablation (RFA).
- Be followed up for 28 days through scheduled phone calls (Day 1, Day 14 ±2) and clinic visits (Day 7 ±1, Day 28 ±2) to assess adverse events, pain, patient comfort, and undergo physical/clinical examinations and ultrasound examinations of the treated area.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ingegerd W Dalfelt, SRN, BSc.
- Numéro de téléphone: +46708433348
- E-mail: ingegerd.dalfelt@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Cathrin Johansson, BSc
- Numéro de téléphone: +46708548834
- E-mail: cathrin.johansson@medvasc.se
Lieux d'étude
-
-
-
Halmstad, Suède, 301 85
- Hallands sjukhus
-
Contact:
- Karin Ludwigs, MD
- Numéro de téléphone: +46 (0)35 14 77 53
- E-mail: Karin.Ludwigs@regionhalland.se
-
Malmö, Suède, 21135
- Scandinavian Venous Centre
-
Contact:
- Karin Ludwigs, MD
- Numéro de téléphone: +46707382447
- E-mail: karin.ludwigs@svcgoteborg.se
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Male or Female >18 years old.
- Subject diagnosed with venous insufficiency in the Great Saphenous Vein from the groin to the proximal 1/3 of the lower leg and with a Clinical Etiological Anatomical Pathophysiological (CEAP) classification of 2 or higher.
- Subject is scheduled for an EVLA or RFA procedure for a unilateral insufficiency of the GSV.
- Subject accepts to be treated with endothermal ablation as a standalone method.
- Subject accepts to be treated without any sedation.
- Subject is willing and able to provide written informed consent.
Exclusion Criteria:
- Considered as being of high risk due to comorbidity in the opinion of the investigator.
- Subject with known and confirmed coagulation defects.
- Subject on anticoagulant treatment.
- Subject who simultaneously needs to be treated with other supplemental techniques such as e.g., foam sclerotherapy, ligation, and phlebectomy.
- Subject with GSV insufficiency in the distal 2/3 of the lower leg.
- Subject, who demands full sedation, or general anesthesia.
- Subject with known allergy to any of the tumescent and/or anesthetizing agents that will be used (per local standard practice) during the endothermal ablation procedure.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Solutio™ catheter used to administrate tumescence during endothermal ablation of varicose veins
Administration of tumescence from inside the vein to the surrounding tissue, via Solutio™ catheter during endothermal ablation of varicose veins.
|
The Solutio™ catheter presents a technique that allows for tumescent anesthesia injections to be administered at selected sites along the vein, from inside the vein to the surrounding tissue. The purpose of the Solutio™ catheter is to prevent the pain associated with multiple injections, through sensitive skin layers along the inner side of the leg, administered prior to ablation. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety related to the procedure using the Solutio™ catheter.
Délai: 28 days
|
Safety evaluated by recording the number and type of adverse device effects (ADEs) and serious adverse device effects (SADEs) related to the procedure using the Solutio™ catheter.
|
28 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient experience of pain
Délai: 28 days
|
The patient will rate their experience of pain at follow up visits at the clinic and via phone contacts.
A Visual Analogue Scale (VAS) measures pain intensity.
The scale consists of a 100 mm line, with two end points representing 0 = "no pain" and 100 = "worst pain imaginable".
The patient will be asked to make a mark across the line according to the maximum experienced pain to indicate their pain at given timepoints.
At phone contacts the patient is asked a standard question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable"
|
28 days
|
|
Physician feedback
Délai: 1 day
|
After the end of the procedure, the physician is asked to provide their feedback, assessment about 10 different aspects during the procedure.
They will answer with a 4-grade scale (1 is excellent, 2 is good, 3 is fair, 4 is impossible /inadequate).
Acceptable score is ≤3 for each question.
|
1 day
|
|
Patient experience of pain
Délai: 28 days
|
At phone contacts the patient is asked a standardized question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable".
|
28 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Michael Akesson, MD, MedVasc AB
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CSDPR901
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .